Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:12 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)
NCT05554354 · National Cancer Institute (NCI) · PHASE2 · terminated · last registry update 2026-03-03 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Other - slow accrual” | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MAP2K1 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-02-25Also stopped (terminated): Gordon Mills, MD, PhD, Capivasertib + Ceralasertib (NCT03801369)
- 2025-11-21Results posted on the registry: Gordon Mills, MD, PhD, Capivasertib + Ceralasertib (NCT03801369)
- 2025-03-24Results posted on the registry: Fundacion Oncosur, Combination, Palbociclib + Binimetinib (NCT04494958)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision